Skip to main content
Clinical Trials/PACTR202107466690046
PACTR202107466690046CompletedPhase 3

Early Prediction and Prevention of Asymptomatic Cardiac Insult in Pediatric Patients with Lysosomal Storage Diseases: (Evaluation of CoQ10 as a Cardioprotective Drug)

Faculty of medecine of Tanta university0 sites20 target enrollmentStarted: June 29, 2021Last updated:

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
Enrollment
20

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
2 Year(s) to 5 Year(s) (—)
Sex
All

Inclusion Criteria

  • Pediatric patients with Lysosomal storage disease aged from 1 to 18 years diagnosed by enzyme assay.

Exclusion Criteria

  • Lysosomal storage disease patients with diabetes mellitus, cancer and bronchial asthma as these diseases may cause cardiac diseases and may alter patient's response to the used drug and may affect the level of the studied biomarkers.

Investigators

Sponsor
Faculty of medecine of Tanta university

Similar Trials